P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR
Market Cap: 95.9m EUR
Have any thoughts about
Pierrel SpA?
Write Note

Relative Value

The Relative Value of one PRL stock under the Base Case scenario is 2.916 EUR. Compared to the current market price of 1.745 EUR, Pierrel SpA is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRL Relative Value
Base Case
2.916 EUR
Undervaluation 40%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
39
Median 3Y
7.3
Median 5Y
10.1
Industry
2.5
Forward
3.1
vs History
73
vs Industry
15
Median 3Y
93.4
Median 5Y
102.9
Industry
21.8
Forward
144
vs History
73
vs Industry
32
Median 3Y
23.1
Median 5Y
42.7
Industry
16.1
vs History
30
vs Industry
16
Median 3Y
30.1
Median 5Y
30.1
Industry
23.8
vs History
58
vs Industry
21
Median 3Y
7.2
Median 5Y
10.1
Industry
2.1
vs History
73
vs Industry
33
Median 3Y
8.2
Median 5Y
10.5
Industry
2.7
Forward
3.7
vs History
73
vs Industry
42
Median 3Y
11.6
Median 5Y
15.6
Industry
5.2
vs History
73
vs Industry
21
Median 3Y
45.5
Median 5Y
57.8
Industry
13.5
Forward
16.3
vs History
73
vs Industry
13
Median 3Y
76.3
Median 5Y
83.3
Industry
16.8
Forward
30.9
vs History
73
vs Industry
28
Median 3Y
25.8
Median 5Y
44.5
Industry
15.2
vs History
vs Industry
Median 3Y
-34
Median 5Y
-69.2
Industry
19.3
vs History
58
vs Industry
38
Median 3Y
3.6
Median 5Y
4.9
Industry
1.9

Multiples Across Competitors

PRL Competitors Multiples
Pierrel SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Pierrel SpA
MIL:PRL
95.9m EUR 2.9 30.6 17.6 31.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 18.5 90.3 48.5 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
IT
P
Pierrel SpA
MIL:PRL
Average P/S: 382 942.2
2.9
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IT
P
Pierrel SpA
MIL:PRL
Average P/E: 32.2
30.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBITDA: 415.4
17.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBIT: 1 813.3
31.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top